查看“EGFR20号外显子插入”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[EGFR]]20号外显子插入</strong>（<strong>[[EGFR]]Exon20 insertions</strong>）是一种极具挑战性的致癌驱动变异，约占<strong>[[非小细胞肺癌]]</strong>（[[NSCLC]]）中[[EGFR]]突变的4%-12%。该变异主要表现为[[EGFR]]激酶结构域[[C-螺旋]]后端的碱基插入或重复。由于其独特的结构构象，[[EGFR]]Exon20ins对传统的第一代至第三代[[EGFR-TKIs]]（如[[吉非替尼]]、[[奥希替尼]]）表现出显著的<strong>[[天然耐药]]</strong>。在精准医学视角下，通过新型[[双特异性抗体]]和高选择性[[小分子]]抑制剂的开发，[[EGFR]]20号外显子插入已由以往的“难治突变”转化为具有明确靶向策略的精准诊疗亚型。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #ffffff 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[EGFR]]Exon20ins</div>
            <div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">20号外显子插入 · 临床分层核心 · 点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 20px; text-align: center; background-color: #f8fafc;">
                <div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;">
                    <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[EGFR]]Exon20插入突变蛋白空间构象模型</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">涉及基因：[[EGFR]] / [[ERBB1]]</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">发生率(NSCLC)</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约2%-3%</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">典型变异位点</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">[[A767_V769dup]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子特征</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[C-螺旋]]空间位移</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">检测金标准</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[NGS]] (二代测序)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">一线治疗</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[含铂双药化疗]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">推荐靶向药</th>
                    <td style="padding: 12px; color: #0f172a;">[[舒沃替尼]]•[[埃万妥单抗]]</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：空间位阻与非配体依赖性激活</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        [[EGFR]]20号外显子插入突变的致癌逻辑不同于经典的[[19外显子缺失]]，其核心生化特征如下：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>构象重塑：</strong>插入的氨基酸通常位于[[C-螺旋]]（[[C-helix]]）后的环区，导致该螺旋向内推移，使激酶域处于持续激活状态，且不依赖于配体结合。</li>
        <li style="margin-bottom: 12px;"><strong>[[ATP]]结合口袋收窄：</strong>这种构象改变导致[[ATP]]结合口袋变得狭窄且具有高度的空间局限性。传统的[[TKIs]]无法与其形成稳定的空间契合，这是导致其天然不敏感的主因。</li>
        <li style="margin-bottom: 12px;"><strong>高度异质性：</strong>目前已鉴定出超过100种不同的[[EGFR]]Exon20ins突变亚型。插入位点的微小差异（如[[近端]]与[[远端]]插入）会显著影响药物的结合亲和力和临床疗效。</li>
        <li style="margin-bottom: 12px;"><strong>信号过载：</strong>突变体持续激活下游[[RAS/MAPK]]、[[PI3K/AKT]]及[[JAK/STAT]]通路，诱导细胞发生恶性转化与抗凋亡反应。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床检测：规避PCR漏检陷阱</h2>

    <div style="overflow-x: auto; margin: 25px auto; width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">检测方法</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">技术局限性/优势</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">临床建议</th>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[ARMS-PCR]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">漏检率极高（约50%），仅能检测预设的已知变异。</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">不建议作为 [[EGFR]]Exon20ins 的常规筛查手段。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[NGS]] (DNA)</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">灵敏度高，可检测长片段插入及罕见未知突变。</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>[[首选方案]]</strong>。应包含覆盖 [[EGFR]] 全外显子的广谱检测。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[RNA-seq]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">可验证复杂的剪接异构体，补充DNA检测的不足。</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">当DNA检测结果可疑时，作为强力的验证辅助。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：从化疗基础到精准打击</h2>
    <p style="margin: 15px 0; text-align: justify;">
        针对[[EGFR]]Exon20ins的管理已由“一刀切”转向精准药物覆盖：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>一线标准治疗：</strong>尽管靶向药物不断涌现，[[含铂双药化疗]]联合或不联合[[贝伐珠单抗]]仍是许多中心的一线标准，具有稳定的获益。</li>
        <li style="margin-bottom: 12px;"><strong>[[双特异性抗体]]：</strong><strong>[[埃万妥单抗]]</strong>（[[Amivantamab]]）通过同时靶向[[EGFR]]和[[MET]]胞外域，并诱导[[ADCC]]效应，打破了小分子药物的空间限制。</li>
        <li style="margin-bottom: 12px;"><strong>高选择性[[TKIs]]：</strong>国产创新药<strong>[[舒沃替尼]]</strong>（[[Sunvozertinib]]）通过优化侧链结构，实现了对20号外显子插入突变的高亲和力结合，在后线治疗中展现了突破性的[[ORR]]。</li>
        <li style="margin-bottom: 12px;"><strong>三代[[TKI]]加量策略：</strong><strong>[[伏美替尼]]</strong>（[[Furmonertinib]]）在加倍剂量（160mg或240mg）下，对特定Exon20ins亚型表现出令人鼓舞的活性。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[HER2]]20号外显子插入：</strong>与[[EGFR]]Exon20ins具有类似的结构病理特征，需通过针对性药物（如[[德曲替康]]）治疗。</li>
            <li style="margin-bottom: 8px;"><strong>[[MET扩增]]：</strong>[[EGFR]]Exon20ins常见的获得性耐药机制之一。</li>
            <li style="margin-bottom: 8px;"><strong>[[埃万妥单抗]]：</strong>目前唯一获批的针对该突变的[[EGFR/MET]]双抗。</li>
            <li style="margin-bottom: 8px;"><strong>[[舒沃替尼]]：</strong>全球范围内在该领域获得突破性疗效认证的国产口服[[TKI]]。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Yasuda H, et al. (2013).</strong> <em>Structural, biochemical, and clinical characterization of EGFR exon 20 insertion mutations in lung cancer.</em> <strong>[[Science Translational Medicine]]</strong>. 5(216):216ra177.[Academic Review]<br>
            <span style="color: #475569;">[权威点评]：该项基石研究系统解析了Exon20ins导致传统TKI耐药的结构基础，为后续药物研发指明了方向。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Remon J, et al. (2020/2025 update).</strong> <em>EGFR exon 20 insertions in advanced non-small cell lung cancer: A new therapeutic target.</em> <strong>[[Cancer Treatment Reviews]]</strong>.<br>
            <span style="color: #475569;">[核心价值]：该综述总结了从化疗时代到免疫靶向时代，针对该罕见突变诊疗标准的演进历程。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            [[EGFR]]20号外显子插入 诊疗生态 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[EGFR]]•[[HER2]]•[[MET]]•[[RAS]]•[[PI3K]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">代表药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[舒沃替尼]]•[[埃万妥单抗]]•[[伏美替尼]]•[[莫博替尼]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td>
                <td style="padding: 10px 15px; color: #334155;">[[Janssen]]•[[Dizal Pharma]]•[[Takeda]]•[[艾力斯医药]]•[[FDA]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td>
                <td style="padding: 10px 15px; color: #334155;">[[针对脑转移的入脑型TKI]]•[[双抗ADC药物研发]]•[[基于超级增强子的转录干预]]</td>
            </tr>
        </table>
    </div>

</div>